Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basal insulin therapy in type 2 diabetes.

M Angelyn Bethel1, Mark N Feinglos

  • 1Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, North Carolina 27710, USA.

The Journal of the American Board of Family Practice
|May 10, 2005
PubMed
Summary

For type 2 diabetes, long-acting insulin agents mimic natural insulin secretion to manage glucose levels. Newer insulins like insulin glargine offer improved basal coverage, reducing hypoglycemia risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

Cardiovascular diabetology·2023
Same author

Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.

Diabetes care·2023
Same author

Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial.

Scandinavian cardiovascular journal : SCJ·2023
Same author

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.

European journal of heart failure·2022
Same author

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.

The Journal of clinical endocrinology and metabolism·2022

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management often progresses from oral agents to insulin therapy.
  • Physiologic insulin secretion involves basal and bolus components to maintain glucose homeostasis.
  • Hypoglycemia is a significant risk associated with insulin therapy.

Purpose of the Study:

  • To discuss the role of insulin therapy in T2DM.
  • To emphasize long-acting insulin agents for basal insulin replacement.
  • To review clinical trials of newer long-acting insulins.

Main Methods:

  • Review of clinical trials focusing on long-acting insulin agents.
  • Emphasis on studies combining basal insulin with oral agents.
  • Analysis of basal-bolus insulin therapy approaches.

Main Results:

  • Long-acting insulins aim to replicate physiologic basal insulin secretion.
  • Newer agents like insulin glargine provide steadier basal coverage.
  • Combination therapies (basal insulin with oral agents or short-acting insulin) are effective.

Conclusions:

  • Basal insulin support is crucial in basal-bolus therapy for T2DM.
  • Modern long-acting insulins offer advantages over traditional formulations.
  • Optimizing insulin therapy improves glucose control and minimizes hypoglycemia risk.

Related Experiment Videos